Payment overview · 2025
General Payments
$208.00
8 reported records · 6 companies
Healthcare provider profile · identity verified
Jean Murphy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PORT CHARLOTTE, FL · NPI 1053372128
Verified facts
What the public records show
CMS Open Payments records show Jean Murphy, M.D. received $208.00 in general payments during 2025 across 8 reported records.
INTUITIVE SURGICAL, INC. accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $84.95 | 40.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.96 | 19.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.95 | 14.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.88 | 9.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.99 | 8.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.27 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.00 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $84.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.96 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.95 | 2 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1392 | 403 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1100 | 341 |
| Amlodipine Besylate | Amlodipine Besylate | 1008 | 309 |
| Lisinopril | Lisinopril | 824 | 254 |
| Levothyroxine Sodium | Levothyroxine Sodium | 715 | 207 |
| Losartan Potassium | Losartan Potassium | 669 | 188 |
| Metformin Hcl | Metformin Hcl | 604 | 184 |
| Tamsulosin Hcl | Tamsulosin Hcl | 423 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 120 |
| Allopurinol | Allopurinol | 317 | 91 |
| Omeprazole | Omeprazole | 310 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 291 | 85 |
| Simvastatin | Simvastatin | 276 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 95 |
| Eliquis | Apixaban | 252 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 71 |
| Furosemide | Furosemide | 231 | 76 |
| Finasteride | Finasteride | 222 | 67 |
| Ezetimibe | Ezetimibe | 219 | 74 |
| Gabapentin | Gabapentin | 203 | 73 |
| Trazodone Hcl | Trazodone Hcl | 182 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 58 |
| Famotidine | Famotidine | 180 | 65 |
| Fenofibrate | Fenofibrate | 157 | 45 |
| Potassium Chloride | Potassium Chloride | 147 | 51 |
| Alendronate Sodium | Alendronate Sodium | 134 | 48 |
| Jardiance | Empagliflozin | 132 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 41 |
| Glimepiride | Glimepiride | 126 | 38 |
| Carvedilol | Carvedilol | 124 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 54 |
| Mounjaro | Tirzepatide | 116 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 25 |
| Tramadol Hcl | Tramadol Hcl | 104 | 38 |
| Sertraline Hcl | Sertraline Hcl | 103 | 32 |
| Atenolol | Atenolol | 102 | 29 |
| Montelukast Sodium | Montelukast Sodium | 101 | 32 |
| Ozempic | Semaglutide | 93 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 24 |
| Donepezil Hcl | Donepezil Hcl | 88 | 33 |
| Alprazolam | Alprazolam | 87 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 27 |
| Meloxicam | Meloxicam | 78 | 24 |
| Methylprednisolone | Methylprednisolone | 78 | 76 |
| Spironolactone | Spironolactone | 76 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 64 |
| Repatha Sureclick | Evolocumab | 70 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 18 |
| Azithromycin | Azithromycin | 62 | 61 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 16 |
| Celecoxib | Celecoxib | 60 | 18 |
| Metformin Hcl Er | Metformin Hcl | 58 | 17 |
| Ramipril | Ramipril | 56 | 13 |
| Januvia | Sitagliptin Phosphate | 55 | 17 |
| Synthroid | Levothyroxine Sodium | 55 | 17 |
| Warfarin Sodium | Warfarin Sodium | 55 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 51 | 18 |
| Valsartan | Valsartan | 50 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Cephalexin | Cephalexin | 45 | 37 |
| Cefdinir | Cefdinir | 43 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 17 |
| Prednisone | Prednisone | 43 | 26 |
| Bupropion Xl | Bupropion Hcl | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 15 |
| Lorazepam | Lorazepam | 41 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 12 |
| Ketoconazole | Ketoconazole | 40 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 26 |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 13 |
| Xarelto | Rivaroxaban | 37 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 34 |
| Azelastine Hcl | Azelastine Hcl | 36 | 15 |
| Irbesartan | Irbesartan | 36 | 11 |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | 11 |
| Temazepam | Temazepam | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 14 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 28 |
| Amoxicillin | Amoxicillin | 28 | 22 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 18 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 16 |
| Primidone | Primidone | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.00 · 8 records | INTUITIVE SURGICAL, INC. | Axonics, Da Vinci Surgical System, EVENITY, Ozempic, PROLIA, QULIPTA, Rybelsus, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error